Abstract
Phenylketonuria (PKU) is a metabolic disorder caused by phenylalanine hydroxylase deficiency leading to increased levels of phenylalanine in the brain. Hyperactivity is reportedly induced by a high level of orexin A, and therefore orexin A content was studied in the PKU mice. Hypothalamus and brain stem had higher levels of orexin A compared to cerebrum and cerebellum both in wild type and PKU mice brains as observed by radioimmunoassay method. Interestingly, all these regions of the brain in PKU mouse showed a higher level of orexin A compared to the wild type. Heart and plasma also had higher levels of orexin A in PKU compared to the wild type. Immunohistochemical analysis revealed an increased number of orexin A–stained cells in the brain and heart of PKU mouse compared to the wild type. This is the first report of increased level of orexin in the PKU mouse brain. Hyperactivity is commonly observed in children with PKU; thus these findings suggest that orexin A is a contributing factor for the hyperactivity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Folling, A. 1934. Uber Ausscheidung von phenylbrenztraubensaure in den Harn als Stoffwechselanomalie in verbingdung mit imbezillitat. Hoppe-Seylers Z. Physiol. Chem. 227:169-176.
Penrose, L. S. 1935. Inheritance of phenylpyruvic amenta (phenylketonuria). Lancet 2:192-194.
Kaufman, S. and Fisher, D. B. 1974. Pterin-requiring aromatic acid hydroxylases, Pages 285-369, in Hayaishi, O. (ed.), Molecular mechanisms of oxygen activation, Academic press, New York.
Lenke, R. R. and Levy, H. L. 1994. Maternal phenylketonuria and hyperphenylalaninemias of man and mouse. Ann. Rev. Genet. 303:1202-1208.
Rouse, B., Lockhart, L., Matalon, R., Azen, C., Koch, R., Hanley, W., Levy, H., Dela Cruz, F., and Friedman, E. 1990. Maternal phenylketonuria pregnancy outcome: A preliminary report of facial dysmorphology and major malformations. J. Inher. Metab. Dis. 13:289-291.
Cowie, V. A. 1971. Neurological and psychiatric aspects of phenylketonuria. Pages 29-39, in Bickel, H., Hudson, F. P., and Woolf, L. I. (eds.), Phenylketonuria and some other inborn errors of aminoacid metabolism, George Thieme Verlag, Stuttgart.
Hendrikx, M. M. T., van der Schot, L. W. A., Slijper, F. M. E., Huisman, J., and Kalverboer, A. F. 1994. Phenylketonuria and some aspects of emotional development. Eur. J. Pediatr. 153:832-835.
Kalverboer, A. F., van der Schot, L. W. A., Hendrikx, M. M. T., Huiman, J., Slijper, F. M. E., and Stemerdink, B. A. 1994. Social behavior and task orientation in early treated PKU. Acta Paediatr. 83(S407):104-105.
Realmuto, G. M., Garfinkel, B. D., Tuchman, M., Tsai, M. Y., Chang, P. N., Pisch, R. O., and Shapiro, S. 1986. Psychiatric diagnosis and behavioral characteristics of phenylketonuric children. J. Nerv. Ment. Dis. 174:536-540.
McDonald, J. D., Dyer, C. A., Gailis, L., and Kirby, M. 1997. Cardiovascular defects among the progeny of mouse phenylketonuria females. Pediatr. Res. 42:103-107.
de Lecea, L., Kilduff, T. S., Peyron, C., Gao, X., Foye, P. E., Danielson, P. E., Fukuhara, C., Battenberg, E. L., Gautvig, B. T., Barlett, F. S., Frankel, W. N., van den Pol, A. N., Bloom, F. E., Gautvik, K. M., and Sutkliff J. G. 1998. The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl. Acad. Sci. USA 95:322-327.
Sakurai, T., Amemiya, A., Ishii, M., Matsuzaki, I., Chemelli, R. M., Tanaka, H., Williams, S. C., Richarson, J. A., Koslowski, G. P., Wilson, S., Arch, J. R., Buckingham, R. E., Haynes, A. C., Carr, S. A., Annan, R. S., McNulty, D. E., Liu, W. S., Terrett, J. A., Elshourbagy, N. A., Bergsma, D. J., and Yanagisawa, M. 1998. Orexins and orexin receptors: A family of hypothalamus neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92:573-585.
Peyron, C., Tighe, D. K., van den pol, A. N., de Lecea, L., Heller, H. C., Sutcliffe, J. G., and Kilduff, T. S. 1998. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurosci. 18:9996-10015.
Nambu, T., Sakurai, T., Mizukami, K., Hosoy, Y., Yanagisawa, M., and Goto, K. 1999. Distribution of orexin neurons in the adult rat brain. Brain Res. 827:243-260.
van den Pol, A. N. 1999. Hypothalamic hypocretin (orexin): Robust innervation of the spinal cord. J. Neurosci. 19:3171-3182.
Samson, W. K., Gosnell, B., Chang, J., Resch, Z. T., and Murphy, T. C. 1999. Cardiovascular regulatory action of hypocretins in brain. Brain Res. 831:248-253.
Shirasaka, T., Takasaki, M., and Kannan, H. 2003. Cardiovascular effects of leptin and orexins. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284:R639-R651.
Hagan, J. J., Leslie, R. A., Patel, S., Evans, M. L., Wattam, T. A., Holmes, S., Benhams, C. D., Tayler, S. G., Routledge, C., Hemmati, P., Munton, R. P., Ashmede, T. E., Shah, A. S., Hatcher, J. P., Hatcher, P. D., Jones, D. E., Smith, M. I., Piper, D. C., Hunter, A. J., Porter, R. A., and Upton, N. 1999. Orexin activates locus coeruleus cell firing and increases arousal in the rats. Proc. Natl. Acad. Sci. USA 96:10911-10916.
Ida, T., Nakahara, K., Katayama, N., Murakami, N., and Nakazato, M. 1999. Effect of lateral cerebroventricular injection of the appetite stimulating neuropeptide, orexin and neuropeptide Y on the various behavioral activities of rats. Brain Res. 821:526-529.
Taylor, M. M. and Samson, W. K. 2003. The other side of the orexins: Endocrine and metabolic actions. Am. J. Physiol. Endocrinol. Metab. 284:E13-E17.
Matalon, R., Rady, P. L., Platt, K. A., Skinner, H. B., Quast, M. J., Campbell, G. A., Matalon, K., Ceci, J. D., Tyring, S. K., Nehls, M., Surendran, S., Wei, J., Ezell, E. L. and Szucs, S. 2000. Knock out mouse for Canavan disease: A mouse model for gene transfer to the central nervous system. J. Gene Med. 2:165-175.
Kurose, T., Ueta, Y., Yamamoto, Y., Serino, R., Ozaki, Y., Saito, J., Nagata, S., and Yamashita, H. 2002. Effects of restricted feeding on the activity of hypothalamic orexin (OX)-A containing neurons and OX2 receptor mRNA level in the paraventricular nucleus of rats. Regul. Peptides 104:145-151.
Pitt, D. B. and Danks, D. M. 1991. The natural history of untreated phenylketonuria over 20 years. J. Pediatr. Child Health 27:189-190.
van der Knapp, M. S. and Valk, J. 1995. Magnetic resonance of myelin, myelination and myelin disorders. Springer, New York.
Matalon, R., Surendran, S., Michals-Matalon, K., Quast, M., Wei, J., Ezell, E., and Szucs, S. 2003. Future role of large neutral aminoacids in the transport of phenylalanine into the brain. Pediatrics (in press).
Taheri, S., Mahmoodi, M., Opacka-Juffry, J., Ghatei, M. A. and Bloom, S. R. 1999. Distribution and quantification of immunoreactive orexin A in rat tissues. FEBS Lett. 457:157-161.
Shirasaka, T., Miyahara, S., Kunitake, T., Jin, Q. H., Kato, K., Takasaki, M., and Kannan, H. 1999. Sympathetic and cardiovascular actions of orexins in conscious rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 277:R1780-R1785.
Matsumura, K., Tsuchihashi, T., and Abe, I. 2001. Central orexin A augments sympathoadrenal outflow in conscious rabbits. Hypertension 3:1382-1387.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Surendran, S., Campbell, G.A., Tyring, S.K. et al. High Levels of Orexin A in the Brain of the Mouse Model for Phenylketonuria: Possible Role of Orexin A in Hyperactivity Seen in Children with PKU. Neurochem Res 28, 1891–1894 (2003). https://doi.org/10.1023/A:1026184127689
Issue Date:
DOI: https://doi.org/10.1023/A:1026184127689